Stromal matrix protein expression following preoperative systemic therapy in breast cancer

Clinical Cancer Research

Volumn 15, Issue 2, 2009, Pages 731-739

  Tokes, Anna Maria ^a,b   Szasz, Attila Marcell ^a   Farkas, Andrea ^a   Toth, Adrienn Lldiko ^a   Dank, Magdolna ^a   Harsanyi, Laszlo ^b   Molnar, Bela Akos ^b   Molnar, Istvan Arthur ^b   Laszlo, Zsolt ^a   Rusz, Zoltan ^a   Kulka, Janina ^a  

^a Schopf Merei Agost Hospital   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; COLLAGEN TYPE 4; MATRIX PROTEIN; MESSENGER RNA; PROTEOGLYCAN; SMOOTH MUSCLE ACTIN; SYNDECAN 1; TENASCIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GROWTH; CONTROLLED STUDY; DISEASE CLASSIFICATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MORPHOMETRICS; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STROMA CELL;

ACTINS; ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CASE-CONTROL STUDIES; COLLAGEN TYPE IV; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; MUSCLE, SMOOTH; NEOADJUVANT THERAPY; PREOPERATIVE CARE; SYNDECAN-1; TENASCIN;

EID: 59449093811     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1523     Document Type: Article

References (50)

1. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998;16:2672-85.
2. Hattangadi J, Park C, Rembert J, et al. Breast stromal enhancement on MRI is associated with response to neoadjuvant chemotherapy. AJR Am J Roentgenol 2008;190:1630-6.
3. Mazouni C, Arun B, Andre F, et al. Collagen IV levels are elevated in the serum of patients with primary breast cancer compared to healthy volunteers. Br J Cancer 2008;99:68-71. Epub 2008 Jun 17.
4. Reardon DA, Zalutsky MR, Akabani G, et al. A pilot study: 1311-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost. Neuro Oncol 2008;10:182-9.
5. Gotte M, Kersting C, Ruggiero M, et al. Predictive value of syndecan-1 expression for the response to neoadjuvant chemotherapy of primary breast cancer. Anticancer Res 2006:26:621 -7.
6. Broet P, Scholl SM, de la Rochefordiere A, et al. Short and long-term effects on survival in breast cancer patients treated by primary chemotherapy: an updated analysis of a randomized trial. Breast Cancer ResTreat 1999:58:151 -6.
7. Cameron DA, Anderson ED, Levack P, et al. Primary systemic therapy for operable breast cancer-10-year survival data after chemotherapy and hormone therapy. Br J Cancer1997;76:1099-105.
8. Shannon C, Smith I. Is there still a role for neoadjuvant therapy in breast cancer? Crit Rev Oncol Hematol 2003;45:77-90.
9. Buzdar AU, Valero V, Ibrahim NK, et al. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 2007:13:228-33.
10. Sachelarie I, Grossbard ML, Chadha M, Feldman S, Ghesani M, Blum RH. Primary systemic therapy of breast cancer. Oncologist 2006;11:574 - 89.
11. Yip GW, Smollich M, Gotte M. Therapeutic value of glycosaminoglycans in cancer. Mol CancerTher 2006;5:2139-48.
12. Morin PJ. Drug resistance and the microenvironment: nature and nurture. Drug Resist Updat 2003;6:169-72.
13. Pupa SM, Giuffre S, Castiglioni F, et al. Regulation of breast cancer response to chemotherapy by fibulin-1. Cancer Res 2007;67:4271 -7.
14. LeBleu VS, Macdonald B, Kalluri R. Structure and function of basement membranes. Exp Biol Med May-wood 2007;232.1121 -9.
15. loachim E, Charchanti A, Briasoulis E, et al. Immunohistochemical expression of extracellular matrix components tenascin, fibronectin, collagen type IV and laminin in breast cancer: their prognostic value and role in tumour invasion and progression. Eur J Cancer 2002;38:2362-70.
16. Barth PJ, Moll R, RamaswamyA. Stromal remodeling and SPARC (secreted protein acid rich in cysteine) expression in invasive ductal carcinomas of the breast. Virchows Arch 2005;446:532-6.
17. Sanderson RD. Heparan sulfate proteoglycans in invasion and metastasis. Semin Cell Dev Biol 2001;12:89-98.
18. Vanhoutte D, Schellings MW, Gotte M, et al. In-creased expression of syndecan-1 protects against cardiac dilatation and dysfunction after myocardial infarction. Circulation 2007;115:475-82.
19. MaedaT, Desouky J, Friedl A. Syndecan-1 expression by stromal fibroblasts promotes breast carcinoma growth in vivo and stimulates tumor angiogenesis. Oncogene 2006;25:1408-12.
20. Baba F, Swartz K, van Buren R, et al. Syndecan1 and syndecan-4 are overexpressed in an estrogen receptor-negative, highly proliferative breast carcinoma subtype. Breast Cancer Res Treat 2006;98:91 -8.
21. Gotte M, Kersting C, Radke I, Kiesel L,Wulfing P. An expression signature of syndecan-1 (CD138), E-cad-herin and c-met is associated with factors of angiogenesis and lymphangiogenesis in ductal breast carcinoma in situ. Breast Cancer Res 2007;9:R8.
22. Jones FS, Jones PL. The tenascin family of ECM glycoproteins: structure, function, and regulation during embryonic development and tissue remodeling. Dev Dyn 2000;218:235-59.
23. Tokes AM, Paku S,Toth S, et al. Tenascin expression in primary and recurrent breast carcinomas and the effect of tenascin on breast tumor cell cultures, Pathol Oncol Res 2000;6:202-9.
24. Ilunga K, Nishiura R, Inada H, et al. Co-stimulation of human breast cancer cells with transforming growth factor-β and tenascin-C enhances matrix met-alloproteinase-9 expression and cancer cell invasion. Int J Exp Pathol 2004;85:373-9.
25. Chevallier B, Roche H, Olivier JP, Chollet P, Hurteloup P. Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol 1993;16:223-8.
26. Sataloff DM, Mason BA, PrestipinoAJ, Seinige UL,Lieber CP, Baloch Z. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg 1995;180:297-306.
27. Hayward JL, Carbone PP, Heusen JC, Kumaoka S, Segaloff A, Rubens RD. Assessment of response to therapy in advanced breast cancer. Br J Cancer 1977:35:292-8.
28. Paska C, Bogi K, Szilak L, et al. Effect of formalin, acetone, and RNAIater fixatives on tissue preservation and different size amplicons by real-time PCR from paraffin-embedded tissue. Diagn Mol Pathol 2004;13:234-40.
29. Pfaffl MW, Horgan GW, Dempfle L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 2002;30:e36.
30. Sjostrom J. Predictive factors for response to chemotherapy in advanced breast cancer. Acta Oncol 2002;41:334-45.
31. Dressman HK, Hans C, Bild A, et al. Gene expression profiles of multiple breast cancer phenotypes and response to neoadjuvant chemotherapy. Clin Cancer Res 2006;12:819-26.
32. Jones RL, Smith IE. Neoadjuvant treatment for early-stage breast cancer: opportunities to assess tumour response. Lancet Oncol 2006;7:869 - 74.
33. MacGrogan G, Mauriac L, Durand M, et al. Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi. Br J Cancer 1996;74:1458-65.
34. Leivonen M, Lundin J, Nordling S, von Boguslawski K, Haglund C. Prognostic value of syndecan-1 expression in breast cancer. Oncology 2004:67:11 -8.
35. Sarkadi B, Homolya L, Szakacs G,Varadi A. Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system. Physiol Rev 2006;86:1179-236.
36. Minchinton AI,Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer 2006;6:583-92.
37. Weaver VM, Lelievre S, Lakins JN, et al. β4 Integrin-dependent formation of polarized three-dimensional architecture confers resistance to apoptosis in normal and malignant mammary epithelium. Cancer Cell 2002;2:205-16.
38. Rintoul RC, SethiT. Extracellular matrix regulation of drug resistance in small-cell lung cancer. Clin Sci Lond 2002;102:417-24.
39. Sethi T, Rintoul RC, Moore SM, et al. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat Med 1999;5:662-8.
40. Nerlich AG, Lebeau A, Hagedorn HG, Sauer U, Schleicher ED. Morphological aspects of altered basement membrane metabolism in invasive carcinomas of the breast and the larynx. Anticancer Res 1998;18:3515-20.
41. Adams AL, Eltoum I, Krontiras H,Wang W, Chhieng DC. The effect of neoadjuvant chemotherapy on histologic grade, hormone receptor status, and Her2/neu status in breast carcinoma. Breast J 2008:14:141 -6.Epub 2008 Jan 31.
42. Bernfield M, Gotte M, Park PW, et al. Functions of cell surface heparan sulfate proteoglycans. Ann Rev Biochem 1999;68:729-77.
43. Alexander CM, Reichsman F, Hinkes MT, et al. Syndecan-1 is required for Wnt-1-induced mammary tumorigenesis in mice. Nat Genet 2000;25:329-32.
44. Jones PL, Jones FS. Tenascin-C in development and disease: gene regulation and cell function. Matrix Biol 2000;19:581 -96.
45. Tsanou E, loachim E, Briasoulis E, et al. Clinicopathological study of the expression of syndecan-1 in invasive breast carcinomas, correlation with extracellular matrix components. J Exp Clin Cancer Res 2004;23:641 -50.
46. Lange K, Kammerer M, Hegi ME, et al. Endothelin receptor type B counteracts tenascin-C-induced endothelin receptor type A-dependent focal adhesion and actin stress fiber disorganization. Cancer Res 2007;67:6163-73.
47. Huang W, Chiquet-Ehrismann R, Moyano JV, Garcia-Pardo A, Orend G. Interference of tenascin-C with syndecan-4 binding to fibronectin blocks cell adhesion and stimulates tumor cell proliferation. Cancer Res 2001;61:8586-94.
48. Sun H, Berquin IM, Owens RT, O'Flaherty JT, Edwards IJ. Peroxisome proliferator-activated receptor γ-mediated up-regulation of syndecan-1 by n-3 fatty acids promotes apoptosis of human breast cancer cells. Cancer Res 2008;68:2912-9.
49. Miyamoto H, Murakami T,Tsuchida K, Sugino H, Miyake H,Tashiro S.Tumor-stroma interaction of human pancreatic cancer: acquired resistance to anticancer drugs and proliferation regulation is dependent on extracellular matrix proteins. Pancreas 2004;28:38-44.
50. Tavazoie SF, Alarcon C, Oskarsson T, et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature 2008;451:147-52.